Branched alpha-glucan, alpha-glucosyltransferase which forms the glucan, their preparation and uses

Patent metadata

Field	Value
Publication number	US-10076130-B2
Application number	US-201615342462-A
Country	US
Kind code	B2
Filing date	Nov 3, 2016
Priority date	Apr 26, 2007
Publication date	Sep 18, 2018
Grant date	Sep 18, 2018

Abstract

The present invention has objects to provide a glucan useful as water-soluble dietary fiber, its preparation and uses. The present invention solves the above objects by providing a branched α-glucan, which is constructed by glucose molecules and characterized by methylation analysis as follows:
(1) Ratio of 2,3,6-trimethyl-1,4,5-triacetyl-glucitol to 2,3,4-trimethyl-1,5,6-triacetyl-glucitol is in the range of 1:0.6 to 1:4; (2) Total content of 2,3,6-trimethyl-1,4,5-triacetyl-glucitol and 2,3,4-trimethyl-1,5,6-triacetyl-glucitol is 60% or higher in the partially methylated glucitol acetates; (3) Content of 2,4,6-trimethyl-1,3,5-triacetyl-glucitol is 0.5% or higher but less than 10% in the partially methylated glucitol acetates; and (4) Content of 2,4-dimethyl-1,3,5,6-tetraacetyl-glucitol is 0.5% or higher in the partially methylated glucitol acetates; a novel α-glucosyltransferase which forms the branched α-glucan, processes for producing them, and their uses.

First claim

The invention claimed is:

1. A method for quality-improving or stabilizing a composition, comprising a step of incorporating a saccharide composition comprising branched α-glucan into the composition to be quality-improved or stabilized;
wherein said saccharide composition comprising branched α-glucan has the following characteristics upon methylation analysis:
(1) Ratio of 2,3,6-trimethyl-1,4,5-triacetyl-glucitol to 2,3,4-trimethyl-1,5,6-triacetyl-glucitol, which indicates the ratio of glucose residues with α-1,4 linkages to glucose residues with α-1,6 linkages, is in the range of 1:0.6 to 1:4;
(2) Total content of 2,3,6-trimethyl-1,4,5-triacetyl-glucitol and 2,3,4-trimethyl-1,5,6-triacetyl-glucitol, which indicates that the total content of glucose residues with α-1,4 linkages and glucose residues with α-1,6 linkages, is 60% or higher in the partially methylated glucitol acetates;
(3) Content of 2,4,6-trimethyl-1,3,5-triacetyl-glucitol, which indicates that the content of glucose residues with α-1,3 linkages, is 0.5% or higher but less than 10% in the partially methylated glucitol acetates; and
(4) Content of 2,4-dimethyl-1,3,5,6-tetraacetyl-glucitol, which indicates that the content of glucose residues with both α-1,3 and α-1,6 linkages, is 0.5% or higher in the partially methylated glucitol acetates; and
wherein said saccharide composition comprising branched α-glucan exhibits osmotic pressure-controlling properties, excipient properties, gloss-imparting properties, moisture-retaining properties, viscosity-imparting properties, adhesion properties, crystallization-inhibiting properties for other saccharides, or low-fermentative properties.

2. The method of claim 1 , wherein said composition is a food, beverage, feed, bait, cosmetic, or pharmaceutical.

3. The method of claim 1 , wherein said saccharide composition comprising branched α-glucan is characterized in that the content of water-soluble dietary fiber of the saccharide composition, obtained by applying a high performance liquid chromatography method, is 40% (w/w) or higher.

4. The method of claim 1 , wherein said saccharide composition comprising branched α-glucan is characterized in that it forms isomaltose in an amount of 25% (w/w) or higher but 50% (w/w) or lower, on a dry solid basis, when the saccharide composition is digested by isomaltodextranase.

Assignees

• Hayashibara Co

Inventors

• Watanabe Hikaru
• Yamamoto Takuo
• Nishimoto Tomoyuki
• Tsusaki Keiji
• Oku Kazuyuki
• Chaen Hiroto
• Fukuda Shigeharu

Classifications

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61P1/02

  Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title